Home
/
Viking Therapeutics, Inc.
/
Financials
/
Quarterly
Viking Therapeutics, Inc. — Quarterly Financials
Quarterly figures from SEC EDGAR XBRL filings (10-Q)
These figures are extracted from XBRL-tagged quarterly reports (10-Q) that Viking Therapeutics, Inc. filed with the SEC. Values are as reported for each individual quarter (Q1, Q2, Q3, Q4) — not cumulative year-to-date. Negative figures indicate a loss.
Revenue — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q1
2018
Mar 31, 2018
$0
May 9, 2018
Q3
2017
Sep 30, 2017
$0
Nov 8, 2017
Q2
2017
Jun 30, 2017
$0
Aug 9, 2017
Q1
2018
Mar 31, 2017
$0
May 9, 2018
Q3
2017
Sep 30, 2016
$0
Nov 8, 2017
Q2
2017
Jun 30, 2016
$0
Aug 9, 2017
Q1
2017
Mar 31, 2016
$0
May 10, 2017
Q3
2016
Sep 30, 2015
$0
Nov 10, 2016
Q2
2016
Jun 30, 2015
$0
Aug 11, 2016
Q1
2016
Mar 31, 2015
$0
May 10, 2016
Q3
2015
Sep 30, 2014
$0
Nov 5, 2015
Q2
2015
Jun 30, 2014
$0
Aug 14, 2015
Q1
2015
Mar 31, 2014
$0
Jun 12, 2015
Revenue — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
$0
Oct 23, 2025
Q2
2025
Jun 30, 2025
$0
Jul 23, 2025
Q1
2025
Mar 31, 2025
$0
Apr 24, 2025
Q3
2025
Sep 30, 2024
$0
Oct 23, 2025
Q2
2025
Jun 30, 2024
$0
Jul 23, 2025
Q1
2025
Mar 31, 2024
$0
Apr 24, 2025
Q3
2024
Sep 30, 2023
$0
Oct 23, 2024
Q2
2024
Jun 30, 2023
$0
Jul 24, 2024
Q1
2024
Mar 31, 2023
$0
Apr 25, 2024
Q3
2023
Sep 30, 2022
$0
Oct 25, 2023
Q2
2023
Jun 30, 2022
$0
Jul 26, 2023
Q1
2023
Mar 31, 2022
$0
Apr 26, 2023
Q3
2022
Sep 30, 2021
$0
Oct 26, 2022
Q2
2022
Jun 30, 2021
$0
Jul 27, 2022
Q1
2022
Mar 31, 2021
$0
Apr 27, 2022
Q3
2021
Sep 30, 2020
$0
Nov 3, 2021
Q2
2021
Jun 30, 2020
$0
Jul 28, 2021
Q1
2021
Mar 31, 2020
$0
Apr 28, 2021
Q3
2020
Sep 30, 2019
$0
Oct 28, 2020
Q2
2020
Jun 30, 2019
$0
Jul 29, 2020
Net Income — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
($90.79M)
Oct 23, 2025
Q2
2025
Jun 30, 2025
($65.56M)
Jul 23, 2025
Q1
2025
Mar 31, 2025
($45.63M)
Apr 24, 2025
Q3
2025
Sep 30, 2024
($24.94M)
Oct 23, 2025
Q2
2025
Jun 30, 2024
($22.25M)
Jul 23, 2025
Q1
2025
Mar 31, 2024
($27.36M)
Apr 24, 2025
Q3
2024
Sep 30, 2023
($22.53M)
Oct 23, 2024
Q2
2024
Jun 30, 2023
($19.23M)
Jul 24, 2024
Q1
2024
Mar 31, 2023
($19.53M)
Apr 25, 2024
Q3
2023
Sep 30, 2022
($15.77M)
Oct 25, 2023
Q2
2023
Jun 30, 2022
($17.43M)
Jul 26, 2023
Q1
2023
Mar 31, 2022
($16.10M)
Apr 26, 2023
Q3
2022
Sep 30, 2021
($13.24M)
Oct 26, 2022
Q2
2022
Jun 30, 2021
($15.38M)
Jul 27, 2022
Q1
2022
Mar 31, 2021
($14.01M)
Apr 27, 2022
Q3
2021
Sep 30, 2020
($9.29M)
Nov 3, 2021
Q2
2021
Jun 30, 2020
($9.57M)
Jul 28, 2021
Q1
2021
Mar 31, 2020
($9.69M)
Apr 28, 2021
Q3
2020
Sep 30, 2019
($5.73M)
Oct 28, 2020
Q2
2020
Jun 30, 2019
($7.67M)
Jul 29, 2020
Operating Income — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
($98.56M)
Oct 23, 2025
Q2
2025
Jun 30, 2025
($74.57M)
Jul 23, 2025
Q1
2025
Mar 31, 2025
($55.47M)
Apr 24, 2025
Q3
2025
Sep 30, 2024
($36.56M)
Oct 23, 2025
Q2
2025
Jun 30, 2024
($34.05M)
Jul 23, 2025
Q1
2025
Mar 31, 2024
($34.07M)
Apr 24, 2025
Q3
2024
Sep 30, 2023
($27.27M)
Oct 23, 2024
Q2
2024
Jun 30, 2023
($23.74M)
Jul 24, 2024
Q1
2024
Mar 31, 2023
($20.54M)
Apr 25, 2024
Q3
2023
Sep 30, 2022
($16.20M)
Oct 25, 2023
Q2
2023
Jun 30, 2022
($17.63M)
Jul 26, 2023
Q1
2023
Mar 31, 2022
($16.25M)
Apr 26, 2023
Q3
2022
Sep 30, 2021
($13.40M)
Oct 26, 2022
Q2
2022
Jun 30, 2021
($15.54M)
Jul 27, 2022
Q1
2022
Mar 31, 2021
($14.23M)
Apr 27, 2022
Q3
2021
Sep 30, 2020
($9.84M)
Nov 3, 2021
Q2
2021
Jun 30, 2020
($10.61M)
Jul 28, 2021
Q1
2021
Mar 31, 2020
($10.95M)
Apr 28, 2021
Q3
2020
Sep 30, 2019
($7.44M)
Oct 28, 2020
Q2
2020
Jun 30, 2019
($9.57M)
Jul 29, 2020